论文信息 - Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman - 字舞流文

Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman

M. Cazzola | C. Pascutto | F. Passamonti | L. Arcaini | E. Rumi | E. Orlandi | M. Lazzarino | E. Brusamolino | L. Malabarba

[1] F. Mandelli,et al. Long‐term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution , 2003, British journal of haematology.

[2] T. Barbui,et al. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. , 2003, Blood.

[3] M. Cazzola,et al. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis , 2002, British journal of haematology.

[4] A. Tefferi,et al. Long-term use of anagrelide in young patients with essential thrombocythemia. , 2001, Blood.

[5] A. Tefferi,et al. A clinical update in polycythemia vera and essential thrombocythemia. , 2000, The American journal of medicine.

[6] J. Laszlo,et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.

[7] J. Dormandy,et al. Leukocytes and the risk of ischemic diseases. , 1987, JAMA.

[8] J. Laszlo,et al. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. , 1986, Seminars in hematology.